Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
Review identifies cannabidiol and other antiepileptic drugs may have direct antitumor effects in central nervous system cancers beyond seizure control.
This review synthesizes evidence suggesting that antiepileptic drugs, including cannabidiol, may exert therapeutic effects in CNS tumors through mechanisms unrelated to seizure suppression. The proposed pathways include metabolic reprogramming, epigenetic modulation, and effects on the tumor immune microenvironment.
For patients with brain tumors who receive antiepileptic drugs for seizure prophylaxis or treatment, these medications may provide additional therapeutic benefit beyond seizure control. This dual mechanism could inform treatment selection and dosing considerations in neuro-oncology practice.
| Study Type | Narrative Review |
| Population | Patients with central nervous system tumors receiving antiepileptic drugs |
| Intervention | Classic antiepileptic drugs (valproic acid, levetiracetam) and novel agents (cannabidiol) |
| Comparator | Not applicable – review study |
| Primary Outcome | Antitumor mechanisms independent of antiepileptic effects |
| Key Finding | Multiple antiepileptic drugs demonstrate potential direct antitumor activity through metabolic, epigenetic, and immunologic pathways |
| Journal | Cells |
| Year | 2024 |
Antiepileptic drugs prescribed to brain tumor patients for seizure management may confer additional antitumor benefits through non-antiepileptic mechanisms. This review provides mechanistic rationale for considering these drugs as potential adjuvant therapies rather than purely supportive care.
This review does not present original clinical trial data demonstrating improved tumor outcomes with antiepileptic drug use. The mechanistic pathways described are largely theoretical and require validation in controlled clinical studies to establish clinical efficacy.
The review synthesizes preclinical and observational data without systematic methodology or quality assessment of included studies. Many proposed mechanisms lack robust clinical validation, and the therapeutic window for antitumor effects versus established antiepileptic dosing remains unclear.
Antiepileptic drugs may offer dual benefits in CNS tumor patients through both seizure control and potential direct antitumor activity. While mechanistically plausible, this hypothesis requires validation through well-designed clinical trials before informing treatment decisions beyond standard seizure management.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Can antiepileptic drugs like cannabidiol help treat brain tumors beyond controlling seizures?
Yes, emerging research indicates that certain antiepileptic drugs (AEDs) including cannabidiol possess direct antitumor activity independent of their seizure control effects. These drugs can impact multiple cellular pathways including metabolic reprogramming, epigenetic regulation, and the tumor immune microenvironment in CNS tumors.
Which antiepileptic drugs show the most promise for brain tumor treatment?
The review highlights both classic AEDs like valproic acid and levetiracetam, as well as novel agents like cannabidiol as having potential antitumor properties. These drugs demonstrate multifaceted mechanisms that could complement traditional cancer therapies for central nervous system tumors.
How do antiepileptic drugs work against brain tumors at the cellular level?
AEDs target multiple cellular mechanisms including metabolic reprogramming of cancer cells, epigenetic modifications, endoplasmic reticulum stress responses, and ion homeostasis disruption. They also appear to modulate the tumor immune microenvironment, potentially enhancing the body’s natural cancer-fighting responses.
Should patients with brain tumors consider adding antiepileptic drugs to their treatment regimen?
While the research is promising, this represents an emerging area requiring further clinical validation. Patients should discuss potential benefits and risks with their oncologist, particularly if they already experience seizures related to their CNS tumor.
What makes this approach different from traditional brain cancer treatments?
This represents a potential multitarget therapeutic strategy that could address both seizure management and tumor progression simultaneously. The approach offers the possibility of repurposing well-established, FDA-approved medications with known safety profiles for expanded cancer treatment applications.
